Study type: Human research · Status: Verified against declared source
Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.
Clinical and experimental medicine · 2025
Study scale: We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.
Abstract only: Open source record
Product or molecular entity relationships
- Humanin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
- MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
This study aimed to evaluate the diagnostic significance of circulating mitochondrial-derived peptides, Humanin and MOTS-c, the long non-coding RNA GAS5, and exosomal microRNAs miR-21 and miR-103 in stratifying prostate diseases, including benign prostatic hyperplasia (BPH), precancerous lesions (PL), and prostate cancer (PCa).
Methods
The online version contains supplementary material available at 10.1007/s10238-025-01810-z.
Scale or participants
We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.
Key findings
This study aimed to evaluate the diagnostic significance of circulating mitochondrial-derived peptides, Humanin and MOTS-c, the long non-coding RNA GAS5, and exosomal microRNAs miR-21 and miR-103 in stratifying prostate diseases, including benign prostatic hyperplasia (BPH), precancerous lesions (PL), and prostate cancer (PCa).
Limitations and uncertainty
In conclusion, the decision tree analysis, based exclusively on three plasma biomarkers (Humanin, MOTS, and GAS5), achieved a cross-validated accuracy of 95%.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.